NT-501

DRUG5 trials

Sponsors

Neurotech Pharmaceuticals, Stanford University

Conditions

GlaucomaMacular Telangiectasia Type 2Macular Telangiectasia Type 2 (MacTel)Retinitis PigmentosaUsher Syndrome Type 2Usher Syndrome Type 3

Phase 2

A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

CompletedNCT00447980

Neurotech PharmaceuticalsRetinitis Pigmentosa

Start: 2007-01-22End: 2010-04-19Updated: 2025-05-01

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

CompletedNCT01530659

Neurotech PharmaceuticalsRetinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3

Start: 2012-01-31End: 2019-07-01Updated: 2023-02-14

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Active, not recruitingNCT04577300

Stanford UniversityGlaucoma

Start: 2021-05-15End: 2026-08-15Target: 30Updated: 2025-11-04

Phase 3

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

CompletedNCT03316300

Neurotech PharmaceuticalsMacular Telangiectasia Type 2 (MacTel)

Start: 2017-11-24End: 2022-09-23Updated: 2024-09-24

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B

CompletedNCT03319849

Neurotech PharmaceuticalsMacular Telangiectasia Type 2

Start: 2018-01-22End: 2022-09-23Updated: 2024-09-24

Related Papers

Long-Term Durability of Ciliary Neurotrophic Factor-Releasing Revakinagene Taroretcel-lwey in Individuals With Retinal Degenerative Disorders.

2025-08-01

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2

NEJM Evidence2025-07-226 citations

Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases.

2012-11-01125 citations